Welcome to our dedicated page for WINDTREE THERAPEUTICS NEW news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on WINDTREE THERAPEUTICS NEW stock.
Windtree Therapeutics, Inc. (WINT) reports developments tied to its transition from a biotechnology-focused company toward a diversified, revenue-generating operating model. Company news has covered material agreements involving cardiovascular drug candidates, licensing activity for acute pulmonary treatments, patent estate updates for istaroxime and SERCA2a activators, and clinical or regulatory disclosures related to heart failure and surfactant-based programs.
Recurring updates also include stockholder approvals, governance matters, capital actions, OTC trading status, and operating and financial results. Windtree’s disclosed product and license references include SURFAXIN®, lyophilized lucinactant, and AEROSURF®, a drug-device combination based on aerosolized KL4 surfactant delivery.
TransCode Therapeutics (RNAZ) announced that Chief Financial Officer and director Tom Fitzgerald has retired and resigned from his roles, effective immediately, on September 10, 2026.
Fitzgerald, who has served as CFO since July 2018, helped guide the company through its initial public offering, the launch of its clinical program for lead candidate TTX-MC138, and its acquisition of Polynoma and license agreement with Oncolytics, which expanded its oncology pipeline. He will continue to provide transition services to the company. John Tattory, a senior finance executive with over 25 years of experience in life sciences, including prior CFO roles and capital-raising responsibilities, has been appointed Interim Chief Financial Officer, effective immediately.
CommLoan announced it has received regulatory approval to operate in all 50 states, enabling interstate commercial mortgage transactions, nationwide broker recruitment, and expanded referral opportunities.
CommLoan also signed a letter of intent for a proposed reverse merger with Windtree Therapeutics (OTCID: WINT) to pursue a public listing; the deal remains subject to definitive agreements and approvals. The company added senior hires across AI, technology, operations, finance, and marketing to support national growth.
Windtree Therapeutics (OTCID: WINT) announced the sale of its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC (SPH) on Dec. 23, 2025. Under the agreement Windtree retains a 20% economic interest in any future milestone, royalty or commercial net revenue SPH receives, including potential global AHF (acute heart failure) commercial revenue if approved.
Windtree will receive a $700,000 cash payment if SPH completes a financing that raises at least $10,000,000. Windtree also transfers certain cardiovascular development payables to SPH, removing those funding obligations from Windtree.
Windtree Therapeutics (OTCID: WINT) announced it has signed a letter of intent dated December 3, 2025 to acquire CommLoan, Inc., a revenue-generating fintech focused on commercial real estate loan origination.
CommLoan will become a subsidiary, retain key employees, and has received bridge financing from Windtree during the transition. Management highlighted CommLoan's proprietary database and software/AI tools as strategic assets to accelerate growth and streamline lending processes.
Windtree Therapeutics (OTCID: WINT) said it may receive up to $78.9 million in development, regulatory and commercial milestone payments plus up to low double‑digit royalties under a global amended and restated license agreement executed in August 2022 for its acute pulmonary franchise including SURFAXIN, lyophilized lucinactant and AEROSURF.
The license partner is responsible for all development and commercialization costs. Windtree said any milestone or royalty receipts would be non‑dilutive and timing/details of potential payments will be communicated in the future.
Windtree Therapeutics (OTCID: WINT) announced allowed patents for istaroxime in Canada (Application No. 3,130,261) and Mexico (Application No. MX/a/2021/010483), and a granted patent for a next-generation pure SERCA2a activator in Israel (Application No. 291412) on Nov 14, 2025.
The company states its cardiovascular patent estate now counts issued/allowed patents and pending applications for istaroxime, dual-mechanism SERCA2a activators, and pure SERCA2a activators, while pursuing partnerships and considering a Phase 3 program for istaroxime based on prior clinical signals of favorable renal outcomes and no increase in arrhythmias.
Windtree Therapeutics (OTCID: WINT) announced on November 13, 2025 that it signed a letter of intent with TESI (OTC: TESI) and will receive $7.5 million in cash and TESI securities under a recently executed termination agreement.
The companies had been pursuing a potential acquisition of Titan Environmental Services, a Michigan waste management business, but mutually agreed to end that process and release reciprocal surviving obligations. Windtree said it will refocus on other opportunities as part of its strategy to become a revenue-generating company.
Windtree Therapeutics (OTCID: WINT) announced stockholder approval of ten key proposals at their Special Stockholder Meeting on August 28, 2025. The company is pivoting towards environmental services and revenue generation, abandoning previously considered cryptocurrency treasury plans.
Key approvals include proposals for environmental services transactions aimed at revenue generation, and an increase in authorized shares from 125 million to 1 billion. The company plans to partner its biotech assets, potentially eliminating $8.8 million in R&D expenses from 2024 related to its cardiovascular program.
The strategic shift focuses on establishing the Windtree Environmental Services division with potential for profitability through future acquisitions.
Windtree Therapeutics (NASDAQ:WINT) announced that its drug candidate istaroxime has been selected for a plenary session presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025. The presentation will focus on interim data from the Phase 2 SEISMiC C study in cardiogenic shock patients.
The interim analysis of the first 20 patients showed promising results with no new safety concerns and no excess arrhythmias when combined with standard therapies. The drug's effects were consistent with previous studies, showing potential benefits for patients with low blood pressure due to heart failure. Notably, cardiogenic shock SCAI Stage C has a 20-30% in-hospital mortality rate.
Windtree Therapeutics (NASDAQ:WINT) has announced positive interim analysis results from its SEISMiC C Phase 2 study evaluating istaroxime in SCAI Stage C cardiogenic shock patients. The study demonstrated that istaroxime maintained its safety profile and showed consistent physiological improvements when combined with current standard treatments.
The global, placebo-controlled, double-blinded trial included sites across the U.S., Europe, and Latin America, building upon previous successful SEISMIC B study results. The interim analysis of the first 20 patients revealed no new safety concerns or excess arrhythmias when istaroxime was administered alongside standard therapies. The company plans to advance to a global Phase 3 trial based on these encouraging results.